Documente Academic
Documente Profesional
Documente Cultură
Dr K Aitken
Clinical research fellow
Dr V Khoo
Consultant clinical oncologist Royal Marsden NHS Foundation Trust email: katharine.aitken@rmh.nhs.uk
Radiotherapy also has a role in the post operative setting. It can be given as adjuvant treatment following surgery to patients with positive margins or high risk factors for recurrence on pathology.6 The current UK RADICALS trial is investigating the optimal timing of radiotherapy (immediately or at the time of PSA confirmed relapse), as well as the value of hormone therapy and its duration (none, six months or two years) in this setting.
Introduction
Prostate cancer is now the commonest malignancy in men in the UK, with 41,000 men being diagnosed in 2010.1 An increase in the use of prostate specific antigen (PSA) testing is thought to account for the rise in prostate cancer incidence and a shift to earlier diagnosis. The majority of men are now diagnosed with asymptomatic localised disease, rather than presenting with locally advanced or metastatic disease. However, it remains the second commonest cause of male cancer death in the UK, with more than 10,000 patients dying from the disease every year.1 Radiotherapy plays an important role in the management of prostate cancer, for both cure and palliation. Herein is provided an overview of the radical use of radiotherapy, focusing on external beam radiotherapy (EBRT) and highlighting some new developments in the area. Prostate cancer staging and management options
Treatment options are dependent on the TNM stage of disease at diagnosis (referring to Tumour, Node, Metastasis staging system using the UICC classification system2), together with other prognostic factors such as PSA level and histological Gleason grade of the tumour. These are used to stratify patients into risk categories that guide potential treatment options (figure 1 and table 1 adapted from MDT Guidance for Prostate Cancer3).
late rectal toxicity by 50% without any reduction in PSAassessed local control rates.9 Subsequently CFRT has permitted the assessment of dose escalation, moving from treating with doses of 64-68Gy to 74-78Gy. The efficacy of dose escalation has been confirmed in a meta-analysis of 2,812 patients, demonstrating a significant reduction in the incidence of biochemical failure in those treated with higher doses.10 However, while dose escalation is an effective means for improving local control, it may come at the expense of increased toxicity unless OARs such as the rectum can be adequately protected from also receiving higher doses. The same meta-analysis confirmed the limitations of using CFRT for dose escalation, with patients receiving high dose CFRT being 1.58 times more likely to develop G2 late GI toxicity than patients who had received conventional doses. In CFRT there is limited scope to physically conform the dose around concave shaped structures, such as the prostate-rectum interface but this can be overcome by newer techniques such as IMRT.
Several methods of IGRT for prostate cancer have been developed. The commonest involves inserting radio-opaque markers or fiducials into the prostate gland, using them as surrogates for the position of the prostate. Daily imaging and on-line set-up correction can then be performed, reducing set-up inaccuracies prior to treatment. IGRT imaging may be 2D, using the position of the fiducials relative to bony landmarks (figure 4), or 3D, such as with kv cone beam, which provides additional cross-sectional information on the prostate position and any gland deformation that has occurred. The use of IGRT in prostate cancer has been shown to improve clinical outcomes. In a retrospective matched cohort analysis, a significant improvement in biochemical tumour control was observed in high risk patients treated with IGRT compared with those who received nonIGRT treatment.16 Areas of focus in IGRT research at present include using fiducial markers to enable intra-fraction tracking of tumour motion (for example using CyberKnife).
Conclusion
Technological advances in imaging and radiotherapy have dramatically changed the treatment of prostate cancer with radiotherapy. Research continues into the optimal volume to be treated in locally advanced cases (ie prostate versus prostate and pelvic nodes) and the value of hypofractionated regimens. The evolution of advanced radiotherapy techniques are permitting research into sub-prostate volume boosting, prostate gland re-irradiation, and treating isolated pelvic nodal recurrences with ablative doses. It is important that these issues are adequately evaluated and assessed, where permissible in comparative studies, so that the potential beneficial outcomes can be quantified.
References
1, Cancer Research UK. Prostate cancer statistics-key facts. Accessed April, 2013; Available from: http://www.cancerresearchuk.org/cancer-info/ cancerstats/keyfacts/prostate-cancer. 2, Available from: http://www.uicc.org. 3, BUG/BAUS/BPG, Multi-disciplinary Team Guidance for Managing Prostate Cancer, 2009. 4, Bolla M et al. Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine 2009;360(24):2516-27. 5, Horwitz E M et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008;26(15): 2497-504. 6, Wiegel T et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 9602/AUO AP 09/95. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009;27(18):2924-30. 7, Khoo V S. Imaging for Radiotherapy Treatment Planning. third ed. Imaging in Oncology, ed. J.R.R. Husband. Chapter 52. 2010, London: Informa UK Ltd. 8, Khoo V S. Conformal Radiotherapy, Intensity-modulated Radiotherapy and Image-guided Radiotherapy. fifth ed. Treatment of Cancer, ed. S.K. Price P, Illidge T. Chapter 53. 2008, London: Hodder Arnold Health Sciences. 9, Dearnaley D P et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999;353(9149):267-72. 10, Viani G A, Stefano E J, Afonso S L. Higher-than-conventional radiation doses in localized prostate cancer treatment; a meta-analysis of randomized, controlled trials. International Journal of Radiation Oncology, Biology, Physics 2009;74(5):1405-18. 11, Chang J H et al. Intensity modulated radiation therapy dose painting for localized prostate cancer using (1)(1)C-choline positron emission tomography scans. International Journal of Radiation Oncology, Biology, Physics 2012;83(5):e691-6. 12, Khoo V. The value of new imaging technology for target volume delineation. European Journal of Cancer 2009;45 Suppl 1:405-8. 13, Zelefsky M J et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2008;70(4):1124-9. 14, Spratt D E et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2013;85(3):686-92. 15, Padhani A R et al. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. International Journal of Radiation Oncology, Biology, Physics 1999;44(3):525-33.
16, Zelefsky M J et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2012;84(1):125-9. 17, Brenner D J et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. International Journal of Radiation Oncology, Biology, Physics 2002;52(1):6-13. 18, Dearnaley D et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer; preliminary safety results from the CHHiP randomised controlled trial. The Lancet Oncology 2012;13(1):43-54.
Figure 1
Possible treatment options Localised (low risk) Active surveillance Radial prostatectomy Radical prostatectomy + post-operative radiotherapy (PORT) EBRT+/- neo-adjuvant and concurrent hormones (6/12) Low dose rate (LDR) brachytherapy +/neo-adjuvant hormones Watchful waiting Novel therapies (eg CyberKnife, HIFU) EBRT +/- HDR brachytherapy boost + long course hormones (three years) Hormone therapy alone
Disease stage Localised (intermediate risk) Localised (high risk) Locally advanced
TABLE 1
Figure 4 Figure 2
Lateral and AP kv images showing prostate fiducial marker position for IGRT. Showing Nucletron brachytherapy needle and template grid for LDR seed insertion.
Figure 5
CyberKnife prostate plan showing (A) typical multiple beam arrangement and (B) axial CT slice showing highly conformal dosimetry with rapid dose fall off.
Figure 3
Five-field prostate IMRT plan showing concave dose shaping at prostate/rectum interface.